Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00067080 · ClinicalTrials.gov registry record · Phase 2
Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 195
- Enrollment target
NCT00067080 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 195 participants.
The verdict
NCT00067080, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 195 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the new orally active iron chelator, ICL670, is as safe as deferoxamine in preventing accumulation of iron in the body while a patient is undergoing repeated blood transfusions.
Interventions
- DRUG ICL670, deferoxamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 195 participants |
| Start Date | 2003-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00067080
The ClinicalTrials.gov registry entry for NCT00067080 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 195 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ICL670, deferoxamine is the first listed.
NCT00067080 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00067080 about?
NCT00067080 is a clinical study titled "Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions". The purpose of this study is to determine if the new orally active iron chelator, ICL670, is as safe as deferoxamine in preventing accumulation of iron in the body while a patient is undergoing repeated blood transfusions.
What is the current status of trial NCT00067080?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 195 participants. The study started on 2003-05.
What interventions are being tested in trial NCT00067080?
The interventions under investigation include: ICL670, deferoxamine (DRUG).
Who is sponsoring clinical trial NCT00067080?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.